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o the Editor:
ith great interest we read the paper by Otto et al. [1] retrospec-
vely reviewing 136 patients with hepatocellular carcinoma
CC) treated with 2 or more cycles of transarterial chemoembol-
ation (TACE) prior to liver transplantation over a period of
3 years. The authors of this single center study suggested that
ot preoperative staging (in or out of Milan criteria) but charac-
risation of tumour response to TACE allows for identiﬁcation of
ﬁndings [4]. However
the data presented is
can be adopted into
changing allocation ru
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only patients were inc
phase after liver tra
provided on time fromatients most suitable for liver transplantation by identiﬁcation
f HCC patients with the most favourable tumour biology. The
urrently accepted concept of ‘‘downstaging’’ is deﬁned by the
eduction of intrahepatic HCC burden in order to achieve 5-year
urvival rates comparable to that of HCC patients to meet trans-
lant criteria without downstaging [2,3]. Therefore, possible
downstaging’’ by response to TACE should not be confused with
favourable tumour biology’’.
We agree with the authors that clinical staging for HCC for
inside’’ or ‘‘outside’’ Milan criteria (MC) may differ in both direc-
ons in up to 25% of cases when compared to histopathology
drop-outs on the waiting list. No lab-MELD data or match-MELD
data at the time of diagnosis or transplant are provided. Speciﬁ-
cally, it remains unclear whether patients who experienced
downstaging by TACE got the beneﬁt of HCC related match-MELD
or were transplanted only after clinical deterioration or with
expanded criteria donor organs directly allocated to the
transplant center.
Seventy-ﬁve patients (55%) suffered from Child-Pugh A cirrho-
sis, 100 patients had only one or two lesions and/ or 120 out of 136
patients had UICC-T1/T2 tumours. Due to the scarcity of available
organs, liver resection in Child-Pugh A cirrhotic patientsmay have
Journal of Hepatology 2014 vol. 60 j 461–467 463
pen access under CC BY-NC-ND license.
oma: size and number of lesions or response to TACE?
79–284.
S, Broelsch CE, Dufour JF, Sherman M. Does a patient
nsplantation after the down-staging of hepatocellular
nspl 2011;17(10):109–116.
, Bossuyt PMM, Gores GJ, Langer B, Perrier Aon behalf of
ensus Group. Recommendations for liver transplantation
carcinoma: an international consensus conference
ol 2012;13:e11–e22. http://dx.doi.org/10.1016/S1470-
ago M, Molmenti E, Paul A, Nadalin S, Brokalaki E, et al.
for hepatocellular carcinoma in cirrhosis: is clinical
n before transplantation realistic? Transplantation
llen JC, Siddiqui FJ, Chan ESY, Tan SB. Systematic review
resection for early hepatocellular carcinoma within the
rg 2012;99:1622–1629.
. Are patients with child’s A cirrhosis and hepatocellular
te candidates for liver transplantation? Am J Transplant
, Nour-Eldin NEA, Rao P, Emami AH, Zangos S, et al.
rial chemoembolization in hepatocellular carcinoma:
neoadjuvant, bridging, and symptomatic indications. EJR
Andreas Paul⇑
Georgios Sotiropoulos
Guido Gerken
Fuat Hakan Saner
General, Visceral, and Transplantation Surgery,
University Hospital Essen,
University Duisburg Essen,
Hufelandstr. 55, Essen, Germany
partment of Gastroenterology and Hepatology,
University Hospital Essen,
University Duisburg Essen,
Hufelandstr. 55, Essen, Germany⇑Corresponding author.
E-mail address: andreas.paul@uk-essen.de
lantation in patients
umber of lesions
rate – when compared with tumours with
ACE – does clearly reﬂect favourable tumour
Letters to the Editor
been in someof thesepatients the treatmentof choice. In fact, it has
to be considered as the gold standard. Additionally, according to a
recently published, well conducted systemic review 5-year sur-
vival rate (including perioperative mortality of up to 5%) after
resection for HCC fulﬁlling MC was 67% (27–81%) [5].
Otto et al. [1] report a similar overall 5-year survival rate of
70% following transplantation, but it remains unclear why resec-
tion was not attempted at least in selected patients in the pre-
sented series.
Furthermore, liver transplantation seems to offer a very
limited 5-year survival beneﬁt in patients with Child-Pugh
A liver cirrhosis when compared with resection (2.8 [4.4–57]
months) or radio frequency ablation (RFA) ± TACE (5.7 [0.7–11.4]
months) [6].
Moreover, TACE alone is nowadays no longer regarded as the
best therapy for inoperableHCC.Combinationwith radiofrequency
ablation, laser induced thermotherapy, selective internal radio-
therapy (SIRT) or transarterial radioembolisation (TARE) can be
more effective and can control the tumour in up to 70% of cases [7].
We therefore think that the data provided by Otto et al. [1] is
less than convincing in that response to repeated TACE should be
used to discriminate between patients with good/acceptable vs.
impaired/inacceptable prognosis for long-term survival after liver
transplantation. In fact, due to multiple biases there is no evi-
dence provided to support this conclusion of the paper.
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To the Editor:
We appreciate the interest of A. Paul et al. in our recent publica-
reduced recurrence
progression during Ttion ‘‘How to decide about liver transplantation in patients with
hepatocellular carcinoma: Size and number of lesions or response
to TACE?’’ [1]. The point in this publication was to demonstrate
the vagueness of size and number of HCC nodules in initial imag-
ing to predict tumour recurrence when compared to the results of
pretransplant transarterial chemoembolization (TACE). Based on
a cohort of 136 patients uniformly treated by repeated TACE,
the results of the radiological routine assessment before the ﬁrst
TACE and after the last TACE before liver transplantation (LT)
were compared. Carcinomas remaining stable or responding to
TACE during pretreatment had a favourable prognosis. Their
biology, and the pre-treatment used in our cohort was obviously
capable of separating two biologically different groups of
patients. The question remains if response to TACE is really a sur-
rogate of tumour biology or if proof of time is crucial in biological
selection. If time before LT is crucial any other form of pre-treat-
ment would yield similar results. Nothing more – but also noth-
ing less – is claimed in our publication. We cannot see the
‘‘confusion’’ in this statement.
Most other aspects criticised by the authors of the letter go
beyond the scope of our publication. This applies for issues such
as drop-out rate including the rate of patients functionally
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